Objective To explore the impact of C1q/tumour necrosis factor-related protein 6(CTRP6)on doxorubicin(DOX)-induced apoptosis and oxidative stress injury of cardiomyocytes,along with its associated mechanism of action.Methods The H9C2 car-diomyocyte injury model was established by dividing the subjects into different groups.These groups included the control group(NS group),the DOX(1μmol/L)group,and the DOX(1μmol/L)group supplemented with CTRP6 at concentration gradients of 0.5 μg/ml,1μg/ml,3μg/ml,and 5μg/ml,respectively.After 24hours of culture,the survival rate of the cardiomyocytes was measured,the results showed that the highest increase in cardiomyocyte survival rate was observed at a CTRP6 concentration of 3 μg/ml,which was selected as the optimal concentration.Subsequently,the experimental groups of H9C2 cardiomyocytes consisted of the control group(NS group),the CTRP6 group,the DOX(1μmol/L)group,and the DOX(1μmol/L)group supplemented with CTRP6(3μg/ml)group.The impact of DOX stimulation on the transcriptional and translational levels of CTRP6 was assessed using fluorescence real-time quantitative polymer-ase chain reaction(RT-qPCR)and Western blot assay.Apoptosis levels were measured using Tunel assay,while enzyme-linked im-munosorbent assay(ELISA)kits were was used to detect the activity of cellular total glutathione peroxidase(GSH-Px)and superoxide dismutase(SOD),as well as the levels of malondialdehyde(MDA).Western blot assay was used to detect the any alterations in the lev-els of AdipoR1 protein and the protein expression of the protein kinase B/glycogen synthase kinase-3 β(Akt/GSK-3 β)signaling path-way.Results Compared with the control group(NS group),the expression levels of CTRP6 protein and mRNA were significantly de-creased in the DOX group(46.26％and 67.74％reduction,respectively,P＜0.05).In contrast,compared with DOX group,the DOX+CTRP6group showed a significant increase in CTRP6 protein expression levels(P＜0.05).Among the different concentrations of CTRP6 added to the DOX+CTRP6group,the survival rate of cardiomyocytes in DOX+3μg/ml CTRP6 treatment group was significantly increased by 26.48％(P＜0.05).Tunel staining revealed a decrease in apoptosis and an upregulation of Bcl-2 expression.In addi-tion,GSH-Px and SOD activities increased by 20.49％and 36.89％respectively,while MDA levels were significantly inhibited(de-creased by 47.09％,P＜0.05).The levels of AdipoR1 protein was significantly increased(P＜0.05).Furthermore,there was a signifi-cant elevation observed in the phosphorylation levels of the Akt/GSK-3β signaling pathway proteins.Conclusion CTRP6 ameliorates DOX-induced apoptosis and oxidative stress injury in cardiomyocytes,possibly through the protective effect of the Akt/GSK-3β signa-ling pathway.

Objective:To analyze the lympho-vascular space invasion (LVSI) in different molecular subtypes of the cancer genome atlas (TCGA) molecular subtypes of endometrial cancer (EC) and to evaluate the prognostic value of LVSI in EC patients with different molecular subtypes.Methods:A total of 258 patients diagnosed EC undergoing surgery in Peking University People′s Hospital from January 2016 to June 2022 were analyzed retrospectively. Among 258 patients, 14 cases were classified as POLE-ultramutated subtype, 43 as high-microsatellite instability (MSI-H) subtype, 155 as copy-number low (CNL) subtype, and 46 as copy-number high (CNH) subtype. Fifty-four patients were positive for LVSI, while 203 tested negative.Results:(1) The incidence of LVSI was found to be highest in the CNH subtype (32.6%,15/46), followed by the MSI-H subtype (27.9%, 12/43), the CNL subtype (16.9%, 26/154), and the POLE-ultramutated subtype (1/14), with statistically significant differences ( χ2=7.79, P=0.044). (2) Staging and deep myometrial invasion were higher in the LVSI positive group than those in the LVSI negative group (all P<0.05), except for the POLE-ultramutated subtype. The grade, lymph node metastasis, and the expression of nuclear antigen associated with cell proliferation (Ki-67) were significantly higher in LVSI positive patients than those in LVSI negative EC patients with both MSI-H and CNL subtypes (all P<0.05). In CNL subtypes patients, LVSI was also associated with age, histology subtype,and progesterone receptor (PR; all P<0.05). (3) Of the 257 EC patients, 25 cases recurred during the follow-up period, with a recurrence rate of 9.7% (25/257); among them, the recurrence rate of LVSI positive patients was 22.2% (12/54), which was significantly higher than those with LVSI negative (6.4%, 13/203; χ2=12.15, P<0.001). During the follow-up period, none of the 14 patients with POLE-ultramutated had recurrence; among CNL patients, the recurrence rate was 19.2% (5/26) in LVSI positive patients, which was significantly higher than that in LVSI negative ones (5.5%, 7/128; χ2=3.94, P=0.047); where as no difference were found in both MSI-H [recurrence rates in LVSI positive and negative patients were 2/12 and 9.7% (3/31), respectively] and CNH subtype [recurrence rates between LVSI positive and negative patients were 5/15 and 9.7% (3/31), respectively] EC patients (both P>0.05). After log-rank test, the 3-year recurrence free survival (RFS) rate were significantly lower in LVSI positive patients from CNL subtype and CNH subtype than those in LVSI negative patients (CNL: 80.8% vs 94.5%; CNH: 66.7% vs 90.3%; both P<0.05). (4) Lymph node metastasis ( HR=6.93, 95% CI: 1.15-41.65; P=0.034) had a significant effect on the 3-year RFS rate of EC patients with MSI-H subtype. Multivariate analysis revealed that PR expression ( HR=0.04, 95% CI: 0.01-0.14; P<0.001) was significantly associated with the 3-year RFS rate of CNL subtype patients. Conclusions:LVSI has the highest positivity rate in CNH subtype, followed by MSI-H subtype, CNL subtype, and the lowest positivity rate in POLE-ultramutated subtype. LVSI is significantly associated with poor prognosis in CNL subtype patients and may affect the prognosis of CNH subtype patients. However, LVSI is not an independent risk factor for recurrence across all four TCGA molecular subtypes.

Background::Non-smokers account for a large proportion of lung cancer patients, especially in Asia, but the attention paid to them is limited compared with smokers. In non-smokers, males display a risk for lung cancer incidence distinct from the females—even after excluding the influence of smoking; but the knowledge regarding the factors causing the difference is sparse. Based on a large multicenter prospective cancer screening cohort in China, we aimed to elucidate the interpretable sex differences caused by known factors and provide clues for primary and secondary prevention.Methods::Risk factors including demographic characteristics, lifestyle factors, family history of cancer, and baseline comorbidity were obtained from 796,283 Chinese non-smoking participants by the baseline risk assessment completed in 2013 to 2018. Cox regression analysis was performed to assess the sex difference in the risk of lung cancer, and the hazard ratios (HRs) that were adjusted for different known factors were calculated and compared to determine the proportion of excess risk and to explain the existing risk factors.Results::With a median follow-up of 4.80 years, 3351 subjects who were diagnosed with lung cancer were selected in the analysis. The lung cancer risk of males was significantly higher than that of females; the HRs in all male non-smokers were 1.29 (95% confidence interval [CI]: 1.20-1.38) after adjusting for the age and 1.38 (95% CI: 1.28-1.50) after adjusting for all factors, which suggested that known factors could not explain the sex difference in the risk of lung cancer in non-smokers. Known factors were 7% (|1.29-1.38|/1.29) more harmful in women than in men. For adenocarcinoma, women showed excess risk higher than men, contrary to squamous cell carcinoma; after adjusting for all factors, 47% ([1.30-1.16]/[1.30-1]) and 4% ([7.02-6.75]/[7.02-1])) of the excess risk was explainable in adenocarcinoma and squamous cell carcinoma. The main causes of gender differences in lung cancer risk were lifestyle factors, baseline comorbidity, and family history.Conclusions::Significant gender differences in the risk of lung cancer were discovered in China non-smokers. Existing risk factors did not explain the excess lung cancer risk of all non-smoking men, and the internal causes for the excess risk still need to be explored; most known risk factors were more harmful to non-smoking women; further exploring the causes of the sex difference would help to improve the prevention and screening programs and protect the non-smoking males from lung cancers.